• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ascendant Resources Announces Results of Annual General Meeting of Shareholders

    6/13/24 5:55:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASND alert in real time by email

    TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.

    A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:

    Number of Directors to be Elected

    On a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approved. The following favourable votes were cast by proxy:

    Total Votes

    % of Votes Cast

    Votes in Favour
    Votes Against

    51,217,885
    279,704

    99.46%
    0.54%

    Total Votes Cast

    51,497,589

    100%

    Election of Directors

    The shareholders elected each of the seven nominees listed in the Company's Management Proxy Circular. Details of the voting results are as follows:

    Name

    Votes in Favour

    %

    Votes Withheld

    %
    Mark Brennan

    50,021,594

    99.07%

    471,462

    0.93%

    Robert Campbell

    50,366,186

    99.75%

    126,870

    0.25%

    Christopher Jones

    50,366,186

    99.75%

    126,870

    0.25%

    Kurt Menchen

    50,366,186

    99.75%

    126,870

    0.25%

    Rui Botica Santos

    50,366,186

    99.75%

    126,871

    0.25%

    Robert Sellars

    50,366,186

    99.75%

    126,870

    0.25%

    Appointment of Auditors

    KPMG LLP was appointed auditor of the Corporation and the directors of the Corporation were authorized to fix the auditor's remuneration. Details of the voting results are as follows:

    Total Votes% of Votes Cast

    Votes in Favour

    51,278,48399.57%

    Votes Withheld

    219,1060.43%

    Total Votes Cast

    51,497,589100%

    The Company also wishes to announce that Stephen Shefsky did not stand for re-election to the Board of Directors of Ascendant Resources. Mr. Shefsky was a co-founder of the Company as well as the Lead Director, serving on the Audit and Corporate Governance committees. Management and the Board wish to express their sincere gratitude to Mr. Shefsky for all his contributions to the Company and wish him the best in future endeavours.

    About Ascendant Resources Inc.

    Ascendant Resources is a Toronto-based mining company focused on the exploration and development of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. The Lagoa Salgada project is a high-grade polymetallic project, demonstrating a typical mineralization endowment of zinc, copper, lead, tin, silver, and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 7,209-hectare property concession.

    Located just 80km from Lisbon and surrounded by exceptional infrastructure, Lagoa Salgada offers a low-cost entry to a significant exploration and development opportunity, already showing its mineable scale and cashflow generation potential.

    Ascendant currently holds an 80% interest in the Lagoa Salgada project through its position in Redcorp - Empreendimentos Mineiros, Lda, ("Redcorp"). The Company's common shares are principally listed on the Toronto Stock Exchange under the symbol "ASND". For more information on Ascendant, please visit our website at http://www.ascendantresources.com/.

    Additional information relating to the Company is available on SEDAR+ at www.sedarplus.ca.

    For further information, contact:

    Mark Brennan
    Executive Chairman
    Mike McAllister
    Vice President, Investor Relations
    Tel: +1-647-805-5662
    [email protected]

    SOURCE: Ascendant Resources, Inc.



    View the original press release on accesswire.com

    Get the next $ASND alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASND

    DatePrice TargetRatingAnalyst
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    1/7/2025$196.00Buy
    UBS
    9/5/2024$180.00Perform → Outperform
    Oppenheimer
    6/25/2024$156.00 → $175.00Hold → Buy
    TD Cowen
    5/31/2024$200.00Buy
    Stifel
    12/20/2023$150.00Buy
    Jefferies
    6/14/2023$89.00Neutral
    Credit Suisse
    More analyst ratings

    $ASND
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascendant Resources Announces Results of Annual General Meeting of Shareholders

      TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv

      6/13/24 5:55:00 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

      COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to

      1/29/24 8:30:00 AM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

      TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Me

      8/23/23 4:48:00 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

      SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

      11/14/24 5:46:12 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

      SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

      11/14/24 2:57:14 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

      SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

      11/14/24 1:28:32 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASND
    Financials

    Live finance-specific insights

    See more
    • Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

      COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 1, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendisphar

      4/24/25 4:01:00 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

      – Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million – Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in Q1 2025, followed by MAA in Q3 2025 – SKYTROFA® full year 2024 revenue was ~€202 million, excluding sales deductions related to prior years, (€197.0 million plus ~€5 million of sales deductions related to prior years) – Total 2024 operating expenses of €598 million – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter an

      2/12/25 4:01:00 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

      COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A

      2/5/25 4:01:00 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendis Pharma upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Ascendis Pharma from Equal-Weight to Overweight and set a new price target of $250.00

      5/5/25 8:26:14 AM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ascendis Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ascendis Pharma with a rating of Outperform and set a new price target of $205.00

      4/16/25 9:07:14 AM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Ascendis Pharma with a new price target

      UBS initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $196.00

      1/7/25 7:40:12 AM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASND
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

      COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle. The bone morphometry data were shared in an oral presentation on May 12 by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada) and

      5/13/25 4:01:00 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

      COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). The PaTH Forward Trial included a 4-week randomized, double-blind, placebo-controlled period followed by an open-la

      5/12/25 4:45:30 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

      COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) being held May 10-13, 2025, in Copenhagen. Four oral presentations will feature Ascendis clinical trial results, including 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism; Week 52 growth and bone morphometry data from the

      5/5/25 8:30:00 AM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASND
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S

      SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

      5/12/25 10:24:40 AM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Ascendis Pharma A/S

      144 - Ascendis Pharma A/S (0001612042) (Subject)

      5/6/25 4:11:31 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Ascendis Pharma A/S

      6-K - Ascendis Pharma A/S (0001612042) (Filer)

      5/1/25 4:46:00 PM ET
      $ASND
      Biotechnology: Pharmaceutical Preparations
      Health Care